| Market Cap | 20.32M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -16.74M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -3.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -31.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -72.00% |
| Recommedations | 2.00 | Quick Ratio | 0.00 | Shares Outstanding | 274.51M | 52W Low Chg | 25.00% |
| Insider Own | 43.16% | ROA | -44.23% | Shares Float | 182.66M | Beta | 0.73 |
| Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.08 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 30,883 | Target Price | - |
| Oper. Margin | - | Earnings Date | - | Volume | 3,000 | Change | -3.23% |
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company was founded in 2001 and is headquartered in Calgary, Canada.